Envoy Medical appoints Charles McKhann as Class I director and to Compensation Committee

Envoy Medical, Inc.

Board size increased from 6 to 7 members; McKhann appointed to Compensation Committee.
Awarded stock options for 100,000 shares at $0.72/share, vesting monthly over 36 months.
McKhann previously CEO of Silk Road Medical (acquired by Boston Scientific) and Apollo Endosurgery (also acquired by Boston Scientific).
McKhann is independent under Nasdaq listing standards and SEC rules.
Appointment effective April 15, 2026; term expires at 2027 annual meeting.

item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Charles S. McKhann

Director

Envoy Medical, Inc.

Effective: 2026-04-15
Filed: Apr 21, 2026 23:59 UTC

On April 15, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the " Board ") of Envoy Medical, Inc. (the " Company "), the Board appointed Charles S. McKhann to serve as a Class I director, with an initial term expiring at the Company’s 2027 annual meeting of stockholders.

Source: SEC EDGAR

accession 0001213900-26-046197

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.